The BayMedica BioSynthesis Platform
InMed’s subsidiary, BayMedica, has created an efficient, patent-pending, biological factory by taking the blueprints for cannabinoid biosynthesis from the cannabis plant and engineering it into ultra-efficient brewer’s yeast. BayMedica utilizes its expertise in synthetic chemistry to complement its biosynthesis platform. BayMedica’s platform has already shown that at scale its cannabinoids have both quality and cost advantages over cannabinoids produced via legacy agriculture.
Harnessing the Power of Cannabinoids
Biosynthesis is a multi-step process where living organisms use enzymes to catalyze the conversion of simple substrates into complex products. Cannabinoids are one class of compounds synthesized by Cannabis, however, the Cannabis sativa plant is an inefficient biological factory for even the most prevalent compounds such as THC and CBD, which comprise only 2-5% of the biomass of the plant. Cannabis is even less efficient at synthesizing the 100+ minor cannabinoids such as CBC, CBDV and THCV that typically comprise less than 0.1% of plant biomass.
The BayMedica platform provides an alternative solution by engineering common yeast to convert sugar into cannabinoids, including common and rare natural varieties, as well as novel cannabinoid analogs of pharmaceutical interest. BayMedica also leverages its experience in synthetic chemistry where applicable. Its cannabinoids have a wide variety of applications in the pharmaceutical, cosmetic, consumer and animal health industries.
Consistent & Pure
- Our products are made through a consistent, reproducible process that results in greater purity and consistency than attained by extracting plant material.
- Our proprietary platform enables the benefits of cannabis without touching the plant.
Rare & Analog Cannabinoids
- We can produce common and rare cannabinoid compounds as well as analog compounds not present in the plant.
Scalable & Cost Effective
- The BayMedica method allows for scalable, cost-effective cannabinoid production.
- Our method is environmentally sustainable, free of pesticides, fertilizers, mold and heavy metals using enclosed bioreactors.
Market Specific Solutions
- BayMedica cannabinoids can be tailored for pharmaceutical, nutraceutical, cosmetic, consumer and animal health markets.
BayMedica's Biosynthesis & Process
Our team of scientists transforms common brewer’s yeast into a biological factory to produce pure individual pharmaceutical-grade cannabinoids from simple sugars. Because the process does not involve plant cultivation and extraction, there are no toxic chemicals, pesticides or heavy metals that are commonly found in cannabis and hemp extracts.
After several days of fermentation the yeast turns the sugars into significant quantities of the target cannabinoid.
Using a proprietary process we separate the yeast cells from the broth to prepare for purification of the cannabinoid.
Purification & Concentration
The next step in the process is purifying the cannabinoid from the yeast cell. Unlike extraction of cannabinoids from plants, where toxins, fertilizers and heavy metals may not be removed, our proprietary technique gently separates and concentrates the cannabinoid.
Natural & Pure Cannabinoids
The result of step three is pure, natural cannabinoids that are identical to the cannabinoid found in the plant. Unlike traditional extraction methods, our process also allows for the production of rare cannabinoids that are found in tiny quantities in the plant.
These pure cannabinoids are then used to produce consumer products such as Prodiol®.
Novel Cannabinoid Analogs
The BayMedica platform also facilitates the production of novel cannabinoid analogs. These compounds are related to naturally occurring cannabinoids, but have been modified to create new chemical entities for novel pharmaceutical development.